Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

More ovarian cancer patients benefit from maintenance combined targeted therapy

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 28.09.19
Views: 493

Prof Isabelle Ray-Coquard - The Université Claude Bernard Lyon, Lyon, France

Prof Isabelle Ray-Coquard speaks to ecancer at ESMO 2019 in Barcelona about the PAOLA-1/ENGOT-ov25 Phase III trial, which showed the benefits of treating advanced ovarian cancer patients with bevacizumab and PARP inhibitor olaparib in the first-line setting.

She explains that this intensive regimen was given to patients both with and without a BRCA mutation. While both groups were found to have extended progression-free survival, this was more pronounced in the subgroup of patients with BRCA mutations and those with homologous recombination deficiency (HRD).

Prof Ray-Coquard comments that these results suggest a new first-line standard of care for patients with advanced ovarian cancer, but she adds that the ability to test patients to determine their outcomes is an important aspect of providing this treatment.

Watch the press conference here.

Watch Dr Susana Banerjee's comment here

Read more about the study here

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

Related videos

follow us

Immuno-oncology advances in cancer treatment e-learning

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation